OCGN Quote, Financials, Valuation and Earnings

Editas Medicine has a net margin of -1036.46% compared to Ocugen's net margin of -1633.49%. Ocugen's return on equity of -215.5% beat Editas Medicine's return on equity of -139.77%.

Ocugen has a consensus price target of $6.50, signalling upside risk potential of 677.42%. On the other hand Editas Medicine has an analysts' consensus of $3.38 which suggests that it could grow by 96.22%. Given that Ocugen has higher upside potential than Editas Medicine, analysts believe Ocugen is more attractive than Editas Medicine.

Ocugen has a beta of 4.214, which suggesting that the stock is 321.428% more volatile than S&P 500. In comparison Editas Medicine has a beta of 2.149, suggesting its more volatile than the S&P 500 by 114.892%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $1.5M, which are smaller than Editas Medicine quarterly revenues of $4.7M. Ocugen's net income of -$15.4M is higher than Editas Medicine's net income of -$76.1M. Notably, Ocugen's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 51.71x versus 3.97x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

EyePoint Pharmaceuticals has a net margin of -1036.46% compared to Ocugen's net margin of -184.82%. Ocugen's return on equity of -215.5% beat EyePoint Pharmaceuticals's return on equity of -55.1%.

Ocugen has a consensus price target of $6.50, signalling upside risk potential of 677.42%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $32.00 which suggests that it could grow by 341.99%. Given that Ocugen has higher upside potential than EyePoint Pharmaceuticals, analysts believe Ocugen is more attractive than EyePoint Pharmaceuticals.

Ocugen has a beta of 4.214, which suggesting that the stock is 321.428% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.581, suggesting its more volatile than the S&P 500 by 58.087%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $1.5M, which are smaller than EyePoint Pharmaceuticals quarterly revenues of $24.5M. Ocugen's net income of -$15.4M is higher than EyePoint Pharmaceuticals's net income of -$45.2M. Notably, Ocugen's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 51.71x versus 7.82x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of -1036.46% compared to Ocugen's net margin of -598.74%. Ocugen's return on equity of -215.5% beat Ocular Therapeutix's return on equity of -56.05%.

Ocugen has a consensus price target of $6.50, signalling upside risk potential of 677.42%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.42 which suggests that it could grow by 117.44%. Given that Ocugen has higher upside potential than Ocular Therapeutix, analysts believe Ocugen is more attractive than Ocular Therapeutix.

Ocugen has a beta of 4.214, which suggesting that the stock is 321.428% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.508, suggesting its more volatile than the S&P 500 by 50.759%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $1.5M, which are smaller than Ocular Therapeutix quarterly revenues of $10.7M. Ocugen's net income of -$15.4M is higher than Ocular Therapeutix's net income of -$64.1M. Notably, Ocugen's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 51.71x versus 22.50x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -1036.46% compared to Ocugen's net margin of 4.19%. Ocugen's return on equity of -215.5% beat TG Therapeutics's return on equity of 19.78%.

Ocugen has a consensus price target of $6.50, signalling upside risk potential of 677.42%. On the other hand TG Therapeutics has an analysts' consensus of $41.20 which suggests that it could grow by 17.45%. Given that Ocugen has higher upside potential than TG Therapeutics, analysts believe Ocugen is more attractive than TG Therapeutics.

Ocugen has a beta of 4.214, which suggesting that the stock is 321.428% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.208, suggesting its more volatile than the S&P 500 by 120.838%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $1.5M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Ocugen's net income of -$15.4M is lower than TG Therapeutics's net income of $5.1M. Notably, Ocugen's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 146.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 51.71x versus 14.60x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.